Literature DB >> 1615141

Hypersensitivity to scopolamine in the elderly.

C Flicker1, S H Ferris, M Serby.   

Abstract

Scopolamine hydrobromide, 0.43 mg/70 kg, was administered by subcutaneous injection to ten young and ten elderly subjects. A comprehensive neuropsychological test battery was used to assess the effects of scopolamine, as compared to placebo, on cognitive function. As previously reported for this group of young subjects, scopolamine significantly impaired performance on tests of recent memory and visuospatial praxis. The same effects were observed in the elderly subjects, but the magnitude of the effects was much larger. The scopolamine injections produced significant psychomotor slowing in the elderly, whereas higher doses of the drug are required to produce this effect in young subjects. In both young and old subjects scopolamine failed to affect immediate memory, language function, object sorting, and the frequency of intrusion errors (although trends toward an effect were more apparent in the elderly). Remote memory, tested in the elderly only, was also unaffected. The results suggest that scopolamine's cognitive effects are quantitatively more pronounced in elderly subjects than young subjects, but that they are qualitatively similar and do not constitute a valid model for the cognitive dysfunction associated with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615141     DOI: 10.1007/bf02245172

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Effects of aging and dementia upon recent visuospatial memory.

Authors:  C Flicker; R T Bartus; T H Crook; S H Ferris
Journal:  Neurobiol Aging       Date:  1984       Impact factor: 4.673

2.  Intrusions as a sign of Alzheimer dementia: chemical and pathological verification.

Authors:  P A Fuld; R Katzman; P Davies; R D Terry
Journal:  Ann Neurol       Date:  1982-02       Impact factor: 10.422

Review 3.  The cholinergic hypothesis of geriatric memory dysfunction.

Authors:  R T Bartus; R L Dean; B Beer; A S Lippa
Journal:  Science       Date:  1982-07-30       Impact factor: 47.728

4.  Implications of memory and language dysfunction in the naming deficit of senile dementia.

Authors:  C Flicker; S H Ferris; T Crook; R T Bartus
Journal:  Brain Lang       Date:  1987-07       Impact factor: 2.381

5.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

6.  Acquisition and retention of categorized material in normal aging and senile dementia.

Authors:  M McCarthy; S H Ferris; E Clark; T Crook
Journal:  Exp Aging Res       Date:  1981       Impact factor: 1.645

Review 7.  Pharmacologic modelling of Alzheimer's disease.

Authors:  T Sunderland; P N Tariot; H Weingartner; D L Murphy; P A Newhouse; E A Mueller; R M Cohen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1986       Impact factor: 5.067

8.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia.

Authors:  W W Beatty; N Butters; D S Janowsky
Journal:  Behav Neural Biol       Date:  1986-03

9.  A visual recognition memory test for the assessment of cognitive function in aging and dementia.

Authors:  C Flicker; S H Ferris; T Crook; R T Bartus
Journal:  Exp Aging Res       Date:  1987       Impact factor: 1.645

10.  Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.

Authors:  T Sunderland; P N Tariot; R M Cohen; H Weingartner; E A Mueller; D L Murphy
Journal:  Arch Gen Psychiatry       Date:  1987-05
View more
  24 in total

1.  Probing peripheral and central cholinergic system responses.

Authors:  C A Naranjo; J Fourie; N Herrmann; K L Lanctôt; C Birt; K K Yau
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

2.  The greater sensitivity of elderly APOE ε4 carriers to anticholinergic medications is independent of cerebrovascular disease risk.

Authors:  Robert D Nebes; Bruce G Pollock; Subashan Perera; Edythe M Halligan; Judith A Saxton
Journal:  Am J Geriatr Pharmacother       Date:  2012-04-24

Review 3.  α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

Authors:  Shizuo Yamada; Yoshihiko Ito; Hideo Tsukada
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

4.  Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles.

Authors:  N Pomara; K Nolan; G Halpern
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

Review 5.  Anticholinergic medication use and dementia: latest evidence and clinical implications.

Authors:  Shelly L Gray; Joseph T Hanlon
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

6.  Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review.

Authors:  Laurine Andre; Adeline Gallini; François Montastruc; Jean-Louis Montastruc; Antoine Piau; Maryse Lapeyre-Mestre; Virginie Gardette
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

7.  Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study.

Authors:  Laurine Andre; Adeline Gallini; François Montastruc; Nicola Coley; Jean-Louis Montastruc; Bruno Vellas; Sandrine Andrieu; Virginie Gardette
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

8.  Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Authors:  Shannon L Risacher; Brenna C McDonald; Eileen F Tallman; John D West; Martin R Farlow; Fredrick W Unverzagt; Sujuan Gao; Malaz Boustani; Paul K Crane; Ronald C Petersen; Clifford R Jack; William J Jagust; Paul S Aisen; Michael W Weiner; Andrew J Saykin
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

9.  Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Authors:  Ricardo Alvarez-Jimenez; Geert Jan Groeneveld; Joop M A van Gerven; Sebastiaan C Goulooze; Anne Catrien Baakman; Justin L Hay; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-07-14       Impact factor: 4.335

10.  Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.

Authors:  Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson
Journal:  JAMA Intern Med       Date:  2015-03       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.